康乃德生物醫藥 CNTB 深 滬
已收盤 04-02 16:00:00 美东时间
2.99
+0.270
+9.93%
華盛通- 最 高3.02
- 今 開2.90
- 成交量 85.92万股
- 最 低 2.72
- 昨 收 2.72
- 總市值 1.67亿
- 52周最高 3.82
- 市盈率 靜 --
- 換手率 1.54%
- 52周最低 0.63
- 委 比 -16.20%
- 總股本 5590.35万
- 歷史最高 29.274
- 量 比 1.14
- 振 幅 11.03%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股夜盘 | Turbo Energy涨24.26%，Robin Energy Ltd.涨23.44%
Turbo Energy涨24.26%；Robin Energy Ltd.涨23.44%；Indonesia Energy Corp Ltd.涨13.25%
04-02 13:01
美股夜盘 | 全球星涨16.74%，Penguin Solutions Incorporation涨10.68%
PMGC Holdings Inc.涨-48.00%；System1 Inc涨-11.69%；中国循环能源涨-9.73%
04-02 08:10
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.30) by 10 percent. This is a 68.75 percent decrease over losses of $(0.16) per share
04-01 05:30
Connect Biopharma Presents Results From Phase 3 52-Week Study In Patients With AD Conducted By Simcere Pharma At 2026 AAD Annual Meeting
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients –– Rademikibart was well tolerated with safety comparable
03-30 19:11
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
Connect Biopharma reported positive results from its Phase 1 study of IV rademikibart, showing rapid and sustained improvements in lung function (FEV1) in asthma and COPD patients. The single 300 mg dose via a 2-minute IV push demonstrated clinically meaningful FEV1 increases of ~200-400 mL as early as 15 minutes, maintained through Day 29, with no serious adverse events. The company expects to report Phase 2 data in mid-2026 and plans to discuss...
03-30 11:00
Connect Biopharma To Present Results Of Phase 3 Study Of Rademikibart In Moderate-To-Severe AD Conducted By Simcere In Late-Breaking Research Session At 2026 AAD Annual Meeting
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today
03-10 21:04
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
Connect Biopharma Holdings Limited will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, at 8:00 a.m. ET. The live webcast and archived replay can be accessed via the Investors section of the Connect website. Connect Biopharma, headquartered in San Diego, focuses on developing therapies for asthma and COPD. The company is advancing rademikibart, an antibody targeting IL-4Rα, with global clinic...
03-03 14:00
Connect Biopharma Expects To Report Topline Data From Phase 1b Intravenous Administration Study In Q1 And Seabreeze STAT Studies In Acute Asthma And COPD Midyear
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –– Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to
01-12 21:12
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
Connect Biopharma announced new data on rademikibart, a potential best-in-class IL-4Rα antibody, highlighting its unique mechanism of action and clinical progress. Phase 1b and 2 studies are ongoing to confirm its rapid improvement in airway function for asthma and COPD, with topline results expected in 2026. The company also reported a strong financial position, with sufficient cash runway into 2027.
01-12 13:00
